Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H1 2020’, provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)

– The report reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Kidney Cancer (Renal Cell Cancer) therapeutics and enlists all their major and minor projects

– The report assesses Kidney Cancer (Renal Cell Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma Plc

4SC AG

Aadi Bioscience Inc

AbbVie Inc

ABL Bio Inc

Acepodia Biotech Inc

Acrotech Biopharma LLC

Actuate Therapeutics Inc

Adaptimmune Therapeutics Plc

ADC Therapeutics SA

Adlai Nortye Biopharma Co Ltd

Advenchen Laboratories LLC

Affimed GmbH

Affitech A/S

Agenus Inc

AIM ImmunoTech Inc

Akeso Inc

Alkermes Plc

Alligator Bioscience AB

Allogene Therapeutics Inc

Almac Discovery Ltd

AlphaMab Co Ltd

Alphamab Oncology

Altor Bioscience LLC

ALX Oncology Inc

Ambrx Inc

Amgen Inc

Amphivena Therapeutics Inc

Anaveon AG

Andes Biotechnologies

Anew Oncology Inc

Anhui Anke Biotechnology (Group) Co Ltd

Antengene Corp

AntiCancer Inc

Apcure SAS

APEIRON Biologics AG

Apexigen Inc

Apollomics Inc

Apotex Inc

Aprea Therapeutics AB

Aravive Inc

Arcus Biosciences Inc

Argenx SE

Arrowhead Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Eastern Biotech Co Ltd

Beijing Foreland Pharma Co Ltd

Beijing Kawin Technology Share-Holding Co Ltd

Benhealth Biopharmaceutical (Shenzhen) Co Ltd

Bio-Path Holdings Inc

Bio-Thera Solutions Ltd

Biocad

Biocon Ltd

Biohaven Pharmaceutical Holding Company Ltd

BioIntegrator Ltd

Bionomics Ltd

BioNTech SE

Biotest AG

BioXpress Therapeutics SA

Boehringer Ingelheim International GmbH

Boryung ViGenCell Inc

Boston Biomedical Inc

BridgeBio Pharma Inc

Bristol-Myers Squibb Co

Byondis BV

Calithera Biosciences Inc

Canget BioTekpharma LLC

CASI Pharmaceuticals Inc

Celldex Therapeutics Inc

Celyad Oncology

Centurion BioPharma Corp

Checkpoint Therapeutics Inc

Chineo Med Beijing Co Ltd

Chipscreen Biosciences Ltd

Cleveland BioLabs Inc

Clovis Oncology Inc

COARE Biotechnology Inc

CoImmune Inc

Constellation Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

CRISPR Therapeutics AG

CSPC Pharmaceutical Group Ltd

CureLab Oncology Inc

Cytocom Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

DevaCell Inc

Dr. Reddy's Laboratories Ltd

Dragonfly Therapeutics Inc

Ecrins Therapeutics SAS

eFFECTOR Therapeutics Inc

EirGenix Inc

Eisai Co Ltd

Eli Lilly and Co

Ellipses Pharma Ltd

EnGeneIC Ltd

Enochian Biosciences Inc

EpimAb Biotherapeutics Inc

Epizyme Inc

Epygen Biotech Pvt Ltd

Ervaxx Ltd

Esanex Inc

Esperance Pharmaceuticals Inc

Evaxion Biotech ApS

Evelo Biosciences Inc

Exelixis Inc

EXUMA Biotech Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Five Prime Therapeutics Inc

Fresenius SE & Co KGaA

GEMoaB Monoclonals GmbH

Gene Techno Science Co Ltd

Genentech Inc

Geneos Therapeutics Inc

Genmab AS

Genocea Biosciences Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

GLG Pharma SA

Glycotope GmbH

Guangzhou Hanghua Bio Pharmaceutical Technology Co

Handa Pharmaceuticals LLC

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

HEC Pharm Co Ltd

Helixmith Co Ltd

Hengenix Biotech Inc

Hibiskus Biopharma Inc

Horizon Therapeutics Plc

Hualan Biological Engineering Inc

Hutchison MediPharma Ltd

Idera Pharmaceuticals Inc

Ikena Oncology Inc

Immune Pharmaceuticals Inc

Immune System Key Ltd

Immune Therapeutics Inc

ImmuneSensor Therapeutics Inc

Immunicum AB

ImmunityBio Inc

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Immunomet Therapeutics Inc

Incyte Corp

Infinity Pharmaceuticals Inc

Inhibrx Inc

Inmune Bio Inc

Innate Pharma SA

InnoCare Pharma Ltd

Innovative Cellular Therapeutics Co Ltd

Innovent Biologics Inc

InSight Biopharmaceuticals Ltd

InteRNA Technologies BV

IO Biotech ApS

Jiangsu Aosaikang Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Jounce Therapeutics Inc

JSK Therapeutics Inc

Jubilant Therapeutics Inc

Karyopharm Therapeutics Inc

Kinnate Biopharma Inc

Komipharm International Co Ltd

Konruns Pharmaceutical Co Ltd

Kuda Therapeutics Inc

Kymab Ltd

Kyowa Kirin Co Ltd

Lantern Pharma Inc

Lead Discovery Center GmbH

Lipac Oncology LLC

Lotus Pharmaceutical Co Ltd

Luye Pharma Group Ltd

Lycera Corp

MacroGenics Inc

Mana Therapeutics Inc

Mantis Therapeutics BV

Marino Biotechnology Co Ltd

MaxiVAX SA

MdBioLab

MediciNova Inc

MedPacto Inc

Merck & Co Inc

Merck KGaA

Mersana Therapeutics Inc

Metagone Biotech Inc

Metis Precision Medicine

Midissia Therapeutics Inc

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Miyarisan Pharmaceutical Company Ltd

Moderna Inc

Modulation Therapeutics Inc

Molecular Partners AG

Molecular Templates Inc

Moleculin Biotech LLC

Multitude therapeutics Inc

MultiVir Inc

Mycenax Biotech Inc

NanoCarrier Co Ltd

Nanology LLC

NantKwest Inc

Nektar Therapeutics

Neoleukin Therapeutics Inc

NeoTX Therapeutics Ltd

Novartis AG

Ocellaris Pharma Inc

Omeros Corp

OncBioMune Pharmaceuticals Inc

OncoImmune Inc

Oncology Venture A/S

Oncology Venture U.S. Inc

Oncolys BioPharma Inc

Oncopeptides AB

Oncorena AB

Oncovir Inc

Ono Pharmaceutical Co Ltd

Orion Corp

Orpheus Therapeutics Inc

Pact Pharma Inc

Peptron Inc

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

Pharmicell Co Ltd

Philogen SpA

Phosplatin Therapeutics LLC

Poseida Therapeutics Inc

Prestige BioPharma Pte Ltd

PsiOxus Therapeutics Ltd

QED Therapeutics Inc

Qilu Puget Sound Biotherapeutics Corp

Qu Biologics Inc

Quadriga BioSciences Inc

Qualigen Therapeutics Inc

RAPT Therapeutics Inc

Regeneron Pharmaceuticals Inc

RemeGen Ltd

Replimune Ltd

RevImmune SAS

Rexahn Pharmaceuticals Inc

Richter Gedeon Nyrt

Rizen (Suzhou) Biosciences Co Ltd

Ryvu Therapeutics SA

Samyang Biopharmaceuticals Corp

Sanofi

Sapphire Biotech Inc

Sareum Holdings Plc

Scancell Holdings Plc

Scholar Rock Inc

Schrodinger LLC

Seneca Therapeutics Inc

Seven and Eight Biopharmaceuticals Corp

Shanghai Junshi Bioscience Co Ltd

Shanghai Pharmaceutical Group Co Ltd

Shattuck Labs Inc

Shijiazhuang Yiling Pharmaceutical Co Ltd

Shionogi & Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Sichuan Huiyang Life Science and Technology Corp

Sichuan Sinovation Bio-technology Co Ltd

SignalRx Pharmaceuticals Inc

Sillajen Biotherapeutics

Sinocelltech Ltd

Sonoval LLC

Sorrento Therapeutics Inc

Sotio AS

Spring Bank Pharmaceuticals Inc

Sprint Bioscience AB

Starpharma Holdings Ltd

Steba Biotech SA

Sumitomo Dainippon Pharma Co Ltd

Suntec Medical (Taiwan) Inc

Surface Oncology Inc

Suzhou Kintor Pharmaceutical Inc

Suzhou Stainwei Biotech Inc

Syndax Pharmaceuticals Inc

Syndivia SAS

Synermore Biologics Co Ltd

T-Cure Bioscience Inc

Tactical Therapeutics Inc

Taiho Oncology Inc

Taiho Pharmaceutical Co Ltd

Tarus Therapeutics Inc

Telix Pharmaceuticals Ltd

Tempest Therapeutics Inc

Teon Therapeutics Inc

TheraPten Biosciences Inc

Torque Therapeutics Inc

Turning Point Therapeutics Inc

TVAX Biomedical Inc

Tyme Technologies Inc

UbiVac LLC

Vaccibody AS

Vault Pharma Inc

Vaxiion Therapeutics Inc

Veana Therapeutics LLC

Vyriad Inc

X4 Pharmaceuticals Inc

Xbrane Biopharma AB

Xcovery Holding Co LLC

Xencor Inc

Xspray Pharma AB

Xynomic Pharmaceuticals Holdings Inc

Y-mAbs Therapeutics Inc

Yuhan Corp

Zelluna Immunotherapy AS

Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd

Table of Contents

Table of Contents

Introduction

Kidney Cancer - Overview

Kidney Cancer - Therapeutics Development

Kidney Cancer - Therapeutics Assessment

Kidney Cancer - Companies Involved in Therapeutics Development

Kidney Cancer - Drug Profiles

Kidney Cancer - Dormant Projects

Kidney Cancer - Discontinued Products

Kidney Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by 4D Pharma Plc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by 4SC AG, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Aadi Bioscience Inc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by AbbVie Inc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by ABL Bio Inc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Acepodia Biotech Inc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Acrotech Biopharma LLC, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Actuate Therapeutics Inc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Adaptimmune Therapeutics Plc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by ADC Therapeutics SA, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Advenchen Laboratories LLC, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Affimed GmbH, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Affitech A/S, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Agenus Inc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by AIM ImmunoTech Inc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Akeso Inc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Alkermes Plc, H1 2020

Kidney Cancer (Renal Cell Cancer) – Pipeline by Alligator Bioscience AB, H1 2020

List of Figures

List of Figures

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports